TYCHON
Website
Leadership
Danny Cunagin, Chief Executive Officer
Carston Wagner, PhD, Chief Scientific Officer
Arek Dudek, PhD, Chief Clinical Specialist
Charles Muscoplat, PhD, Chief Commercial Officer
Jake Petersburg, PhD, Sr. Research Scientist
Founded
2015
Industry
Immunotherapy Technology
Tychon is a pre-clinical biotech company developing a novel immuno-therapy technology to treat blood and solid cancers. The Company’s off-the-shelf protein-based therapy is designed to bind to a person’s existing immune cells (T-cells), transforming them into cancer killing cells. Unlike other immunotherapies challenged by side effects, Tychon’s therapy can be controlled or switched off with a common antibiotic. Tychon anticipates a significant market advantage for cancer patients with respect to cost, rapid availability and safety.